CEO loans Catheter Precision $500K at 8%; enters royalty agreement for LockeT device

Catheter Precision, Inc.

CEO David Jenkins loaned $500,000 via 8% promissory note due August 30, 2024.
Royalty agreement with co-inventor Auston Locke: 5% net sales of LockeT device until $1M, then 2% up to $10M; ends Dec 31, 2033 or patent expiry.
Jenkins and affiliates hold >10% common stock, Series X preferred convertible into >8M shares, and 11.77% royalty on LockeT sales.
Missiaen Huck, Jenkins' adult daughter, serves as non-executive COO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.